<?xml version="1.0" encoding="UTF-8"?>
<p>While vaccine development has an obvious high priority, much attention has also been given in the press and in discussions of the White House Task Force to the development of effective antiviral drugs. Drugs may have a greater chance of early success. Thus far, the public discourse has generated significant confusion and misconception. The President has touted the benefits of hydroxychloroquine (HQ) and advocated its off‐label use, and the FDA has surprisingly endorsed his position by granting an emergency approval for COVID‐19 patients. The laboratory evidence that HQ has antiviral effects is minimal. It suppresses viral replication only at very high, nonpharmacological drug concentrations 
 <xref rid="onco13337-bib-0004" ref-type="ref">4</xref>. The clinical evidence for HQ efficacy comes from several conflicting reports from China and an article in the International 
 <italic>Journal of Antimicrobial Agents</italic>
 <xref rid="onco13337-bib-0005" ref-type="ref">5</xref>, describing a poorly performed, uncontrolled French study, which has been sharply criticized by the journal sponsor, the International Society of Antimicrobial Chemotherapy 
 <xref rid="onco13337-bib-0005" ref-type="ref">5</xref>.
</p>
